Chronic Myeloid Leukemia In a Pregnant Woman: A Case Report

Year 2015, Volume: 40 Issue: 4, 811 - 813, 05.10.2015

Aytekin Tokmak , Ali Güzel Ahmet Yalınkaya

https://doi.org/10.17826/cutf.85458

Abstract

Chronic myeloid leukemia (CML) is a rare disease in pregnancy. Our aim is to present a 37 weeks of pregnant woman with chronic myelogenous leukemia. A 27 Years in multigravi (gravida 5, parity: 4), at 37 weeks gestation was admitted with the diagnosis of painful pregnancy and CML. Physical examination findings were normal, complete blood count and peripheral blood smear results were consistent with CML. The patient was diagnosed CML in the 30th week of pregnancy and were treated with hydroxyurea and interferon. Treatment depends on the mother and the fetus did not develop any side effects. Our patient with CML is interesting due to lack of perinatal effects and take the diagnosis at an early age. CML diagnosed during pregnancy requires a multidisciplinary approach and hydroxyurea and interferon treatment on the mother and fetus are at low risk of inducing adverse effects.

Keywords

CML, pregnancy, hydroxyurea, interferon

Gebelikte Kronik Miyeloid Lösemi: Olgu Sunumu

Abstract

Kronik miyeloid lösemili (KML) gebelikte çok nadir görülen bir hastalıktır. Amacımız 37 haftalık gebeliği olan kronik miyeloid lösemili olgunun sunulmasıdır. Bir 27 yaşında multigravida (gravida :5, parite:4), 37. gebelik haftasında sancılı gebelik ve KML tanılarıyla kabul edildi. Fizik muayene bulguları normal olan hastanın tam kan sayımı ve periferik yayma sonuçları KML ile uyumluydu. Gebeliğinin 30. haftasında KML tanısı alan hastaya hidroksiüre ve interferon tedavisi uygulandı. Tedaviye bağlı anne ve fetüste herhangi bir yan etki gelişmedi. Olgumuz KML tanısını erken yaşta alması ve perinatal etkilerinin olmaması nedeniyle ilginçtir. ebelik sırasında tanı konulan KML multidisipliner bir yaklaşım gerektirir ve hidroksiüre ve interferon tedavisinin anne ve fetüs üzerinde olumsuz etkiler oluşturma riski düşüktür.

Keywords

KML, gebelik, hidroksiüre, interferon

References

• Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenousleukemia: biology and therapy. Ann Intern Med 1999;131:207–19.
• Mughal TI, Goldman JM. Chronic myeloid leukaemia: STI 571 magnifiesthe therapeutic dilemma. Eur J Cancer. 2001;37:561–8.
• Lichtman M, Leisveld J. Acute myelogenous leukemia. In: Beutler E,Lichtman M,Coller B et al (Eds). Williams Hematology (ed 6). New York, NY,McGraw-Hill 2001:1047-84.
• Zuazu J, Julia A, Sierra J et al. Pregnancy outcome in hematologic malignencies. Cancer. 1991;67:703-9.
• Mclain CR. Leukemia in pregnancy. Clin Obstet Gynec. 1974;17:185-94.
• Buekers TE, Lallas TA. Chemotherapy in pregnancy. Obstet Gynecol ClinNorth Am. 1998;25:323–9.
• Celiloglu M, Altunyurt S, Undar B. Hydroxyurea treatment for chronic myeloid leukemia during pregnancy. 2000;79:803-4
• Reichel RP, Linkesch W, Schetitska D. Therapy with recombinant interferon alpha-2c during unexpected pregnancy in a patient with chronic myeloid leukaemia. Br J Haematol. 1992;82:472–8.
• YadavU, Solanki SL, Yadav R. Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyureaand imatinib continued 2013;9:484-6. doi: 10.4103/0973-1482.119305.
• Bazarbashi MS, Smith MR, Karanes C et al, Succesful management of Ph choromosome choronic myelogenous leukemia with leukapheresis during pregnancy. Amer J Hematol. 1991;38:235-7.